The FDA granted 510(k) clearance to Ibex Prostate Detect (formerly known in the U.S. as Galen Second Read), an artificial-intelligence software device from Ibex Medical Analytics that analyzes scanned whole-slide images of prostate core needle biopsies and generates heatmaps to help pathologists identify small or easily missed areas of prostate cancer — the company’s first FDA clearance. Real-world institutional validation of the underlying Galen(TM) Prostate AI algorithm was published in Modern Pathology (PMID 38868487): integrated into routine clinical practice at a CLIA-certified pathology laboratory over 3 years, examining more than 122,000 slides and 9,200 cases, the algorithm showed 96.6% sensitivity and 96.7% specificity for prostate cancer detection. Company-reported precision and clinical validation studies conducted at multiple US and European laboratories, cited as part of the FDA clearance package, found a 99.6% positive predictive value for the system’s cancer heatmaps and identified missed cancers in a meaningful share of biopsies initially read as benign — this record has not independently confirmed those specific company-reported figures against a primary regulatory document and reports them as claimed, not verified.

The MASAI randomized controlled trial reports that AI-supported mammography increased cancer detection while reducing radiologist reading workload, compared to standard double reading. Primary publication: PMID 39904652, https://pubmed.ncbi.nlm.nih.gov/39904652/, DOI https://doi.org/10.1016/S2589-7500(24)00267-X. Trial registry: https://clinicaltrials.gov/study/NCT04838756. This is a randomized controlled trial in a specific screening-program population and health-system context — it must not be summarized as AI replacing radiologists, as AI mammography being universally superior across every health system, or as increased detection alone proving a mortality-reduction benefit (a separate, longer-term outcome this detection-focused trial does not itself establish). Population/health-system context must remain visible in any summary. This story is intended to replace prior anecdotal/commercial AI-breast-screening coverage with this randomized-trial evidence. [Identifiers as supplied, attributed to independent verification outside this environment — not independently re-verified live here.]